Study Design Considerations for Evaluating Efficacy of Systemic Preexposure Prophylaxis Interventions | Zendy

Deborah Donnell | Zendy; James P. Hughes | Zendy; Lei Wang | Zendy; Ying Qing Chen | Zendy; Thomas R. Fleming | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Study Design Considerations for Evaluating Efficacy of Systemic Preexposure Prophylaxis Interventions

Author(s) -

Deborah Donnell,

James P. Hughes,

Lei Wang,

Ying Qing Chen,

Thomas R. Fleming

Publication year - 2013

Publication title -

jaids journal of acquired immune deficiency syndromes

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.162

H-Index - 157

eISSN - 1944-7884

pISSN - 1525-4135

DOI - 10.1097/qai.0b013e3182986fac

Subject(s) - emtricitabine , pre exposure prophylaxis , medicine , dosing , clinical trial , psychological intervention , placebo , food and drug administration , efficacy , human immunodeficiency virus (hiv) , clinical endpoint , clinical study design , research design , intensive care medicine , drug , alternative medicine , pharmacology , family medicine , viral load , antiretroviral therapy , psychiatry , men who have sex with men , social science , syphilis , pathology , sociology

The development of interventions for systemic pre-exposure prophylaxis (PrEP) faces several significant challenges following the US Food and Drug Administration's approval of emtricitabine/tenofovir (FTC/TDF) for HIV prevention. This development is particularly complex because of inconsistency of efficacy results of FTC/TDF PrEP trials for HIV prevention.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research